Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of “Buy” from Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has received an average rating of “Buy” from the fifteen brokerages that are presently covering the company, Marketbeat reports. Fifteen analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $216.07.

Several equities analysts have recently issued reports on ASND shares. Royal Bank of Canada lifted their price target on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, May 2nd. Wedbush upped their target price on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an “outperform” rating in a research note on Friday, May 2nd. JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an “overweight” rating in a research report on Friday, May 2nd. Evercore ISI upped their price objective on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an “outperform” rating in a research report on Friday, May 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $200.00 target price on shares of Ascendis Pharma A/S in a report on Monday, May 12th.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $161.57 on Wednesday. The firm has a market capitalization of $9.85 billion, a P/E ratio of -22.76 and a beta of 0.41. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $183.00. The company’s 50-day simple moving average is $157.53 and its 200 day simple moving average is $143.01.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million. On average, equities research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC boosted its position in shares of Ascendis Pharma A/S by 3.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company’s stock worth $368,000 after purchasing an additional 100 shares during the period. Legato Capital Management LLC lifted its stake in shares of Ascendis Pharma A/S by 7.5% during the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock valued at $264,000 after buying an additional 134 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in Ascendis Pharma A/S by 2.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,578 shares of the biotechnology company’s stock worth $1,337,000 after buying an additional 195 shares during the period. Jones Financial Companies Lllp increased its stake in Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after buying an additional 197 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Ascendis Pharma A/S during the fourth quarter valued at about $28,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.